Literature DB >> 35904411

Characterization and Prediction of Signal Intensity Changes in Normal Liver Parenchyma on Gadoxetic Acid-enhanced MRI Scans after Liver-directed Radiation Therapy.

Anthony D Nehlsen1, Kunal K Sindhu1, Thomas Wolken1, Fahad Khan1, Christopher K Kyriakakos1, Stephen C Ward1, Erin Moshier1, Bachir Taouli1, Michael Buckstein1.   

Abstract

Purpose To better characterize and understand the significance of focal liver reaction (FLR) development in a large cohort of patients who underwent gadoxetic acid-enhanced MRI after being treated with radiation therapy (RT) for hepatobiliary tumors. Materials and Methods This retrospective study evaluated 100 patients (median age, 65 years [first and third quartiles, 60-69 years]; 80 men) who underwent RT for hepatocellular carcinoma, bile duct tumors, or liver metastases at Mount Sinai Hospital between March 1, 2018, and February 29, 2020. CT simulation scans were fused to MRI scans obtained 1-6 months and 6-12 months after RT, using the hepatobiliary phase of the MRI. To define FLR volume, two radiation oncologists independently delineated the borders of the hypointensity observed on MRI scans in the liver region where RT was delivered. Biologically effective dose (BED) thresholds for the formation of FLRs were calculated, along with albumin-bilirubin (ALBI) scores and grades, and overall survival. Results Most patients developed FLRs, which decreased in volume over time. Median BED threshold values for FLR development were 63.6 Gy at 1-6 months and 88.7 Gy at 6-12 months. While higher baseline ALBI scores were associated with a lower rate of FLRs, there was a significant association between FLR volume and increase in ALBI score at 1-6 months (P = .048). Twelve- and 24-month survival estimates for the cohort were 81% and 48%, respectively. Histopathologic analysis of seven explanted liver specimens demonstrated findings consistent with radiation-induced liver disease. Conclusion FLRs were a clear measure of liver damage after RT and were associated with the development of liver dysfunction and focal radiation-induced liver disease. Keywords: MRI, Radiation Therapy Supplemental material is available for this article. © RSNA, 2022.

Entities:  

Keywords:  MRI; Radiation Therapy

Mesh:

Substances:

Year:  2022        PMID: 35904411      PMCID: PMC9358658          DOI: 10.1148/rycan.210100

Source DB:  PubMed          Journal:  Radiol Imaging Cancer        ISSN: 2638-616X


  34 in total

1.  Quasi-likelihood estimation for relative risk regression models.

Authors:  Rickey E Carter; Stuart R Lipsitz; Barbara C Tilley
Journal:  Biostatistics       Date:  2005-01       Impact factor: 5.899

2.  The expression of transporter OATP2/OATP8 decreases in undetectable hepatocellular carcinoma by Gd-EOB-MRI in the explanted cirrhotic liver.

Authors:  Masaaki Hidaka; Mitsuhisa Takatsuki; Sadayuki Okudaira; Akihiko Soyama; Izumi Muraoka; Takayuki Tanaka; Izumi Yamaguchi; Takanobu Hara; Hisamitsu Miyaaki; Tatsuki Ichikawa; Tomayoshi Hayashi; Ichiro Sakamoto; Kazuhiko Nakao; Tamotsu Kuroki; Takashi Kanematsu; Susumu Eguchi
Journal:  Hepatol Int       Date:  2012-06-24       Impact factor: 6.047

3.  Grid analysis improves reliability in follicle counts made by ultrasonography in women with polycystic ovary syndrome.

Authors:  Marla E Lujan; Eric D Brooks; Anna L Kepley; Donna R Chizen; Roger A Pierson; Andrew K Peppin
Journal:  Ultrasound Med Biol       Date:  2010-04-09       Impact factor: 2.998

4.  A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research.

Authors:  Terry K Koo; Mae Y Li
Journal:  J Chiropr Med       Date:  2016-03-31

Review 5.  Dose to organ at risk and dose prescription in liver SBRT.

Authors:  Rives Michel; Izar Françoise; Parent Laure; Modesto Anouchka; Portier Guillaume; Kirzin Sylvain
Journal:  Rep Pract Oncol Radiother       Date:  2017-04-17

6.  Quantitative evaluation of liver function with T1 relaxation time index on Gd-EOB-DTPA-enhanced MRI: comparison with signal intensity-based indices.

Authors:  Kiyohisa Kamimura; Yoshihiko Fukukura; Tomohide Yoneyama; Koji Takumi; Akihiro Tateyama; Aya Umanodan; Toshikazu Shindo; Yuichi Kumagae; Shin-ichi Ueno; Chihaya Koriyama; Masayuki Nakajo
Journal:  J Magn Reson Imaging       Date:  2013-11-05       Impact factor: 4.813

7.  Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).

Authors:  Louise J Murray; Jenna Sykes; James Brierley; John J Kim; Rebecca K S Wong; Jolie Ringash; Tim Craig; Michael Velec; Patricia Lindsay; Jennifer J Knox; Laura A Dawson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-04-12       Impact factor: 7.038

Review 8.  Imaging-Based Liver Function Tests--Past, Present and Future.

Authors:  D Geisel; L Lüdemann; B Hamm; T Denecke
Journal:  Rofo       Date:  2015-07-31

Review 9.  Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: imaging evaluation post treatment.

Authors:  Trenton Kellock; Teresa Liang; Alison Harris; Devin Schellenberg; Roy Ma; Stephen Ho; Wan Wan Yap
Journal:  Br J Radiol       Date:  2018-02-01       Impact factor: 3.039

10.  Focal hepatic lesions in Gd-EOB-DTPA enhanced MRI: the atlas.

Authors:  José Traila Campos; Claude B Sirlin; Jin-Young Choi
Journal:  Insights Imaging       Date:  2012-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.